Singapore: AMRI has extended a commercial supply relationship to supply aminobisamide hydrochloride (ABA) to GE Healthcare. ABA is an intermediate material used in diagnostic imaging agents. This substantial contract commitment positions AMRI as a strategic supplier to GE Healthcare.

Production will continue at AMRI's large scale manufacturing subsidiary located in Rensselaer, US. The new contract extends through December 31, 2016, and replaces the existing supply contract between GE and AMRI that has been in effect since 2005.

"We are pleased to once again extend our long-term relationship with GE Healthcare," said AMRI chairman, CEO and president, Dr Thomas E D'Ambra. "The renewal of this relationship underscores the confidence that premier global pharmaceutical and healthcare companies have in AMRI's ability to meet their critical product needs.

Dr D'Ambra continued, "The ABA product relationship with GE Healthcare has been an important one for AMRI since acquisition of the Rensselaer plant in 2003 and at this time is our largest commercial supply arrangement. We continue to be pleased with the progress that we are making in our large scale manufacturing business segment, the largest component of which is our Rensselaer site."

"We are adding new customers and new products at this facility, along with continuing the long term relationships, like GE Healthcare, that have formed the basis of our revenue stream. The extension of this key, long term agreement provides a consistent and high quality revenue source for this business unit through 2016," added Dr D'Ambra.